USPTO serial 98697887
SHAREVAC
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Oct 7, 2025
- Examiner
- SCHRADER, BRITTANY A
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with SHAREVAC?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Tubingen, DE
Tubingen, DE
Tubingen, DE
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jennifer Fraser
Jennifer Fraser Dykema Gossett PLLC1301 K Street, NW, Suite 1100 WestWashington, DC 20005United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals and biomolecules, in particular biological macromolecules, for industrial or scientific purposes; Reagents for research purposes | ACTIVE | — |
| 005 | Chemical preparations for medical use, in particular biological macromolecules, for therapeutic and preventive treatment of tumor diseases, infectious diseases, autoimmune disorders and allergies, for treatment of inherited genetic diseases or for protein or enzyme replacement therapy, and for treatment of neurological, neuromuscular, neurodegenerative and cardiovascular diseases, and for treatment of metabolic disorders; Pharmaceutical preparations namely, immunostimulants, in particular for human or veterinary medical purposes; pharmaceutical preparations, namely, vaccines, in particular for human or veterinary medical purposes; pharmaceutical preparations, namely, adjuvant immunostimulants; pharmaceuticals and medicaments containing biological macromolecules, in particular for human or veterinary purposes for the treatment of neurological, neuromuscular, neurodegenerative and cardiovascular diseases, for the treatment of infectious diseases, autoimmune diseases and tumours, for treatment of cancers, for treatment of metabolic diseases and for treatment of heritable genetic diseases and for protein or enzyme replacement therapy; Pharmaceuticals preparations and medicines based on biological macromolecules for the treatment of neurological, neuromuscular, neurodegenerative and cardiovascular diseases, for the treatment or prevention of infectious diseases, allergies, autoimmune disorders and tumour diseases, for the treatment of metabolic disorders and for the treatment of inherited genetic diseases or for protein or enzyme replacement therapy; Gene therapeutic preparations being Nucleic acid macromolecules for in vivo or in vitro expression for human and veterinary use; Dietetic substances adapted for medical use, in particular substances for food supplements; Vaccines | ACTIVE | — |
| 007 | Bioreactors for use in manufacturing biopharmaceuticals; Filling machines, in particular for use for filling biopharmaceutical compositions into containers; Industry roboters being industrial robots | ACTIVE | — |
| 009 | Scientific and laboratory apparatus for chemical synthesis; laboratory equipment, namely, mobile laboratory equipped with scientific or laboratory apparatus for chemical synthesis; laboratory equipment, namely, mobile laboratory equipped with scientific or laboratory apparatus for purification and analysis of synthesized compounds; laboratory equipment, namely, mobile device for the synthesis of macromolecules; Scientific and laboratory apparatus for chemical or biological analysis and/or synthesis; laboratory equipment, namely, mobile production station of biological macromolecules for laboratory or and for cell culturing for therapeutic use; Bioreactors for laboratory or and for cell culturing for therapeutic use | ACTIVE | — |
| 042 | Scientific and technological services, namely, and scientific research , in particular for identification, testing and characterisation of biological molecules; scientific research in the nature of pre-clinical and clinical testing of macromolecules for others; Custom synthesis of chemical compounds, in particular biological macromolecules | ACTIVE | — |
| 044 | Medical and veterinary services, in particular for therapeutic and preventive treatment of tumour diseases, infectious diseases, autoimmune disorders and allergies, for the treatment of inherited genetic diseases or for protein or enzyme replacement therapy, and for the treatment of neurological, neuromuscular, neurodegenerative and cardiovascular diseases, and for the treatment of metabolic disorders; Vaccination services in the nature of administering vaccines to patients | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by CureVac SE
- Other trademarks owned by CureVac SE
- Other trademarks owned by CureVac SE
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 007
- Other trademarks in Class 009
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named SHAREVAC
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 7, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Oct 7, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 19, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 19, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 13, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 14, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 3, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 3, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 3, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 4, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 4, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 4, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 20, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 17, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 14, 2024 | NWAP | NEW APPLICATION ENTERED | — |